(VNDA) Vanda Pharmaceuticals - Ratings and Ratios

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is a biopharmaceutical company specializing in the development and commercialization of innovative therapies addressing significant unmet medical needs. The companys marketed products include HETLIOZ® (tasimelteon), a melatonin receptor agonist for non-24-hour sleep-wake disorder; Fanapt® (iloperidone), an atypical antipsychotic for bipolar I disorder and Parkinsons disease psychosis, with a long-acting injectable (LAI) formulation under development for schizophrenia; and Ponvory® (ponesimod), a sphingosine 1-phosphate receptor modulator for treating psoriasis and ulcerative colitis. These products underscore Vandas focus on neurological and inflammatory disorders.

The companys pipeline is diverse and targets multiple therapeutic areas. HETLIOZ® is being investigated for jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric non-24-hour sleep-wake disorder. Fanapt®s LAI formulation aims to enhance treatment adherence in schizophrenia. Bysanti, a novel antipsychotic, is in development for bipolar I disorder, schizophrenia, and major depressive disorder. Tradipitant (VLY-686), an NK-1 receptor antagonist, is being studied for gastroparesis, motion sickness, and atopic dermatitis. Imsidolimab, an IL-36R antagonist, targets generalized pustular psoriasis. VTR-297, a histone deacetylase inhibitor, shows promise in hematologic malignancies and oncology. VQW-765, a nicotinic acetylcholine receptor partial agonist, is under investigation for performance anxiety and psychiatric disorders.

Vandas early-stage portfolio includes cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors, such as VSJ-110 for dry eye and ocular inflammation, and VPO-227 for secretory diarrhea disorders like cholera. Antisense oligonucleotide molecules, including VCA-894A for Charcot-Marie-Tooth Disease Type 2S (CMT2S) and VGT-1849A for polycythemia vera, highlight the companys commitment to rare genetic disorders. Founded in 2002 and headquartered in Washington, D.C., Vanda Pharmaceuticals leverages its expertise in central nervous system and inflammatory disorders to develop targeted therapies.

Ticker Symbol: VNDA
Exchange: NASDAQ
Type: Common Stock
Country Origin: United States
GICS Sub Industry: Biotechnology

Average Volume 20d: 712,607
Last Price: $4.76
SMA 20: $4.57
SMA 50: $4.60
SMA 200: $5.06
ATR: $0.19

Market Cap: $314.86M USD
P/E: 0.00
P/E Forward: 30.30
P/B: 0.49
P/S: 1.32
RoE: -3.51

3-Month Forecast:
Technical Outlook:VNDAs stock price is currently below its 20-day and 50-day moving averages, indicating bearish momentum. The 200-day moving average at $5.06 suggests resistance. With an ATR of $0.19, volatility is moderate. Expect sideways movement with potential downside risk.
Fundamental Outlook:Vandas negative return on equity and high forward P/E ratio of 30.30 signal high valuation expectations amid current losses. The price-to-sales ratio of 1.32 reflects moderate revenue multiples. The stock may face headwinds due to profitability concerns and rich valuations.